Lampire fully understands the pricing pressures inherent in the biotechnology marketplace. During our 45+ years of serving both the diagnostic and pharmaceutical industries, we have always strived to find innovative methods of providing excellent value propositions to our clients. Unfortunately, as you are no doubt aware, we are operating under a different business paradigm post-Covid, and all components of operational cost continue to escalate. We find ourselves with no alternative but to implement the first price increase in three years on selected polyclonal antibody services effective December 1, 2022.